Tag Archives: AZD0780

Lilly Enters Licensing Agreement for Long-Acting Therapies in CVRM; Hims & Hers Reduces Workforce; AstraZeneca Initiates Ph3 Oral PCSK9i Program 

Three cardiometabolic-related news items have been observed: Lilly entered into a licensing agreement with Camurus for long-acting drug delivery technology (view press release); Hims & Hers plans to cut 4% of its workforce (view article); and AstraZeneca initiated its Ph3 AZURE program for AZD0780 (oral PCSK9i) in patients with HeFH (AZURE-HeFH; view CT.gov record), elevated LDL (AZURE-LDL; view CT.gov record), and a CVOT (AZURE-Outcomes; view CT.gov record). Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Register
Already a member? Log in here

Novo Partners with Telehealth Providers; AstraZeneca, Pfizer, Novartis, and Regeneron Q1 ’25 Earnings; Abbott and Epic CGM Integration; Eversense 365 to Integrate with twiist AID System

A series of cardiometabolic-related news items has been observed from Novo Nordisk, AstraZeneca, Pfizer, Novartis, Regeneron Pharmaceuticals, Abbott, and Sequel Med Tech/Senseonics. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Register
Already a member? Log in here

AZ and Viking Q4 ’24 Earnings

Two cardiometabolic-related news items have been observed: AstraZeneca (view press release; view slides) and Viking Therapeutics (view press release) hosted their respective Q4 ’24 earnings calls. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Register
Already a member? Log in here

AZ Buys Oral GLP-1RA; Q3 ’23 Earnings Update

AstraZeneca hosted its Q3 ’23 earnings call (press release; slides) and provided updates to its CVRM business, including insight on its newly acquired oral GLP-1RA. Just prior to the earnings release, AZ announced it entered into an exclusive licensing agreement for ECC5004, a QD oral GLP-1RA, from Eccogene (view press release). Below, FENIX provides highlights and insights from the call, including thoughts on AZ’s decision to acquire the new oral GLP-1RA.

This content is for Read Less members only.
Register
Already a member? Log in here